A Phase 2 Study to Evaluate the Safety, Tolerability, and Immune Response of AFX3772 Vaccine in Healthy Infants

NCT05412030 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

388

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumonia, Bacterial
Pneumococcal Infections
Pneumonia, Pneumococcal

Interventions

BIOLOGICAL: AFX3772
BIOLOGICAL: Prevnar 13
BIOLOGICAL: Prevnar 20

Sponsor

GlaxoSmithKline